--- title: "Boston Scientific: Business Model" description: "Boston Scientific revenue by business segment and geography from its fiscal 2025 Form 10-K, with each part's share, growth and profitability explained." canonical: https://www.getswoopr.com/stocks/companies/boston-scientific/business-model/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Boston Scientific: Business Model & Revenue Engine ## Direct Answer Boston Scientific reports revenue across 2 business segments in its fiscal 2025 Form 10-K. Cardiovascular is the largest, with $13.3 billion of revenue (66% of the total), followed by Medsurg at $6.8 billion (34%). 64% of revenue came from the United States. ## How Does Boston Scientific Make Money? Cardiovascular supplies 66% of revenue, so Boston Scientific's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, Cardiovascular grew fastest (+23.2%) and Medsurg slowest (+13.9%), so the revenue mix tilts toward Cardiovascular while that gap lasts. | Segment | FY2025 revenue | FY2024 revenue | Share of revenue | Change | | --- | --- | --- | --- | --- | | Cardiovascular | $13.3 billion | $10.8 billion | 66.0% | 23.2% | | Medsurg | $6.8 billion | $6.0 billion | 34.0% | 13.9% | ![Bar chart of Boston Scientific revenue by segment for fiscal 2025: Cardiovascular 66.0%, Medsurg 34.0%.](https://www.getswoopr.com/images/charts/boston-scientific-business-model-segment-mix.webp) *Boston Scientific revenue by segment as a share of total revenue, from the table above. The largest is highlighted. Select the chart to open it full size.* ## Where Does Boston Scientific's Revenue Come From? Regions follow the definitions in the filing; most companies assign revenue by customer location. | Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change | | --- | --- | --- | --- | --- | | United States | $12.9 billion | $10.2 billion | 64.1% | 26.0% | | EMEA | $3.5 billion | $3.2 billion | 17.2% | 6.9% | | Asia Pacific | $3.1 billion | $2.7 billion | 15.3% | 14.7% | | Emerging Markets | $3.0 billion | $2.7 billion | 14.9% | 11.4% | | Latin America and Canada | $678 million | $624 million | 3.4% | 8.7% | ## What the Segment Figures Do Not Show The rows above add up to 100% of Boston Scientific's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin. ## Where These Numbers Come From Every figure on this page is a value Boston Scientific reported in the segment note and revenue disclosures of its Form 10-K filed February 17, 2026 (accession 0000885725-26-000010), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading. Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation. ## Frequently Asked Questions ### What are Boston Scientific's business segments? In its fiscal 2025 Form 10-K, Boston Scientific reports revenue for Cardiovascular and Medsurg. ### Which part of Boston Scientific brings in the most revenue? Cardiovascular, with $13.3 billion of revenue in fiscal 2025, or 66% of the total. ### How much of Boston Scientific's revenue comes from outside the United States? 36% in fiscal 2025, by the geographic breakdown Boston Scientific reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies. ## References - [SEC EDGAR: BOSTON SCIENTIFIC CORP Form 10-K filed February 17, 2026](https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm) - [SEC EDGAR: BOSTON SCIENTIFIC CORP annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=885725&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) - [SEC: Financial Statement Data Sets](https://www.sec.gov/data-research/sec-markets-data/financial-statement-data-sets) ## Related Pages - [Boston Scientific company dossier](https://www.getswoopr.com/stocks/companies/boston-scientific/) - [Boston Scientific financial metrics](https://www.getswoopr.com/stocks/companies/boston-scientific/metrics/) - [Boston Scientific financial risk indicators](https://www.getswoopr.com/stocks/companies/boston-scientific/risks/) - [Boston Scientific peer comparison](https://www.getswoopr.com/stocks/companies/boston-scientific/competitors/) - [Boston Scientific business model and revenue mix](https://www.getswoopr.com/stocks/companies/boston-scientific/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).